Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Product Name : ABX464
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etrasimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of Arena Pharmaceuticals
Details : Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulato...
Product Name : APD334
Product Type : Other Small Molecule
Upfront Cash : $6,700.0 million
November 03, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Lead Product(s) : Etrasimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Pfizer to Acquire Arena Pharmaceuticals
Details : Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena and it's pipeline including lead product etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in development for a range of immuno-inf...
Product Name : APD334
Product Type : Other Small Molecule
Upfront Cash : $6,700.0 million
December 13, 2021
Lead Product(s) : Etrasimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition